[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc, 2008, 83(5):584-594.
[4] ETTINGER D S, WOOD D E, AGGARWAL C, et al. NCCN guidelines insights:non-small cell lung cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2019, 17(12):1464-1472.
[5] DOROSHOW D B, HERBST R S.Treatment of advanced non-small cell lung cancer in 2018[J]. JAMA Oncol, 2018, 4(4):569-570.
[6] WEI S C, DUFFY C R, ALLISON J P.Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8(9):1069-1086.
[7] BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
[8] BRAHMER J, RECKAMP K L, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
[9] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
[10] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK):a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265.
[11] RECK M, RODRIEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833.
[12] MOK T, WU Y L, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830.
[13] SEZER A, KILICKAP S, GUMUS M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%:a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274):592-604.
[14] LANGER C J, GADGEEL S M, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer:a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11):1497-1508.
[15] GANDHI L, RODRIGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092.
[16] RODRIGUEZ-ABREU D, POWELL S F, HOCHMAIR M J, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC:protocol-specified final analysis from KEYNOTE-189[J]. Ann Oncol, 2021, 32(7):881-895.
[17] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051.
[18] ZHOU C, CHEN G, HUANG Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer(CameL):a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305-314.
[19] YANG Y, ZHOU H, ZHANG L.Response to letter to the editor:efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC:a randomized, double-blind, phase 3 study(ORIENT-11)[J]. J Thorac Oncol, 2020, 15(12):e191-e192.
[20] LU S, LU Y, YU X, et al. 1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC[J]. Ann Oncol, 2020, 31(Suppl 4):S816-S817.
[21] ZHOU C, WU L, FAN Y, et al. LBA56 ORIENT-12:Sintilimab plus gemcitabine and platinum(GP) as first-line(1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer(sqNSCLC)[J]. Ann Oncol, 2020, 31(Suppl 4):S1186.
[22] WANG J, LU S, YU X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(5):709-717.
[23] ROBERT L, RIBAS A, HU-LIESKOVAN S.Combining targeted therapy with immunotherapy.Can 1+1 equal more than 2?[J]. Semin Immunol, 2016, 28(1):73-80.
[24] PROTO C, FERRARA R, SIGNORELLI D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer(NSCLC):what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75:39-51.
[25] OXNARD G R, YANG J C, YU H, et al. TATTON:a multi-arm, phase Ⅰb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020, 31(4):507-516.
[26] HELLMANN M D, CIULEANU T E, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104.
[27] RAMALINGAM S S, CIULEANU T E, PLUZANSKI A, et al. Nivolumab+ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer:three-year update from CheckMate 227 Part 1[J]. J Clin Oncol, 2020, 38(15 Suppl):9500.
[28] RECK M, CIULEANU T E, DOLS M C, et al. Nivolumab(NIVO)+ipilimumab(IPI)+2 cycles of platinum-doublet chemotherapy(chemo) vs 4 cycles chemo as first-line (1L) treatment(tx) for stage Ⅳ/recurrent non-small cell lung cancer(NSCLC):CheckMate 9LA[J]. J Clin Oncol, 2020, 38(15 Suppl):9501.
[29] ERINJERI J P, FINE G C, ADEMA G J, et al. Immunotherapy and the interventional oncologist:challenges and opportunities-a society of interventional oncology white paper[J]. Radiology, 2019, 292(1):25-34.
[30] CHANG X, LU X, GUO J, et al. Interventional therapy combined with immune checkpoint inhibitors:Emerging opportunities for cancer treatment in the era of immunotherapy[J]. Cancer Treat Rev, 2019, 74:49-60.
[31] DENG L, LIANG H, BURNETTE B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2):687-695.
[32] HERRERA F G, BOURHIS J, COUKOS G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin, 2017, 67(1):65-85.
[33] SHI L, CHEN L, WU C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22(5):1173-1184.
[34] DEIPOLYI A R, BROMBERG J F, ERINJERI J P, et al. Abscopal effect after radioembolization for metastatic breast cancer in the setting of immunotherapy[J]. J Vasc Interv Radiol, 2018, 29(3):432-433.
[35] ERINJERI J P, THOMAS C T, SAMOILIA A, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10[J]. J Vasc Interv Radiol, 2013, 24(8):1105-1112.
[36] YIN J, DONG J, GAO W, et al. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage Ⅳ nonsmall cell lung cancer[J]. Medicine(Baltimore), 2018, 97(44):e13112.
[37] DUFFY A G, ULAHANNAN S V, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):545-551.
[38] WANG S, ZHANG J, MENG F J, et al. Combination of pembrolizumab and (125) I attenuates the aggressiveness of non-small cell lung cancer[J]. Oncol Lett, 2020, 19(6):4142-4150.
[39] BACKLUND M, FREEDMAN J.Microwave ablation and immune activation in the treatment of recurrent colorectal lung metastases:a case report[J]. Case Rep Oncol, 2017, 10(1):383-387.
[40] YAKKALA C, CHIANG C L L, KANDALAFT L, et al. Cryoablation and immunotherapy:an enthralling synergy to confront the tumors[J]. Front Immunol, 2019, 10:2283.
[41] RODRIGUEZ-ABREU D, JOHNSON M L, HUSSEIN M A, et al. Primary analysis of a randomized, double-blind, phase Ⅱ study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab(atezo) versus placebo plus atezo as first-line(1L) treatment in patients with PD-L1-selected NSCLC(CITYSCAPE)[J]. J Clin Oncol, 2020, 38(15 Suppl):9503.
[42] POSTOW M A, SIDLOW R, HELLMANN M D.Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2):158-168.
[43] BERTRAND A, KOSTINE M, BARNETCHE T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies:systematic review and meta-analysis[J]. BMC Med, 2015, 13:211.
[44] WANG Y, ZHOU S, YANG F, et al. Treatment-related adverse events of pd-1 and pd-l1 inhibitors in clinical trials:a systematic review and Meta-analysis[J]. JAMA Oncol, 2019, 5(7):1008-1019.
[45] SHOUSHTARI A N, FRIEDMAN C F, NAVID-AZARBAIJANI P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma[J]. JAMA Oncol, 2018, 4(1):98-101.
[46] WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and Meta-analysis[J]. JAMA Oncol, 2018, 4(12):1721-1728.
[47] CURRY J L, TETZLAFFM T, NAGARAJAN P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy[J]. J Cutan Pathol, 2017, 44(2):158-176.
[48] MIN L C, LI S, TRAN D C, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes:a retrospective case-control study[J]. J Am Acad Dermatol, 2018, 79(6):1047-1052.
[49] PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1):1-28.
[50] ABU-SBEIH H, ALI F S, ALSAADI D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis:a multi-center study[J]. J Immunother Cancer, 2018, 6(1):1-11.
[51] HAANEN J, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):v264-v266.
[52] ZHANG L, JONES-O'CONNOR M, AWADALLA M, et al. Cardio-toxicity of immune checkpoint inhibitors[J]. Curr Treat Options Cardiovasc Med, 2019, 21(7):1-17.
[53] SIU L L, EVEN C, MESIA R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-Low/Negative recurrent or metastatic HNSCC:the phase 2 CONDOR randomized clinical trial[J]. JAMA Oncol, 2019, 5(2):195-203.
[54] RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128. |
